《M4E THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE EFFICACY – M4E(R1) CLINICAL OVERVIEW AND CLINICAL SUMMARY OF MODULE 2 MODULE 5 CLINICAL STUDY REPORTS》由会员分享，可在线阅读，更多相关《M4E THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE EFFICACY – M4E(R1) CLINICAL OVERVIEW AND CLINICAL SUMMARY OF MODULE 2 MODULE 5 CLINICAL STUDY REPORTS（53页珍藏版）》请在金锄头文库上搜索。
1、 INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE COMMON TECHNICAL DOCUMENT FOR THE REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE EFFICACY M4E(R1) CLINICAL OVERVIEW AND CLINICAL SUMMARY OF MO
2、DULE 2 MODULE 5 : CLINICAL STUDY REPORTS Current Step 4 version dated 12 September 2002 This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final
3、 draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA. M4E(R1) Document History First Codification History Date New Codification November 2005 M4E Approval by the Steering Committee under Step 2 and release for public consultation. 20 July 2000 M4E M4E Appr
4、oval by the Steering Committee under Step 4 and recommendation for adoption to the three ICH regulatory bodies. 8 November 2000 M4E Current Step 4 version M4E Approval by the Steering Committee of Numbering and Section Headers changes for consistency directly under Step 4 without further public cons
5、ultation. 12 September 2002 M4E(R1) In order to facilitate the implementation of the M4E guideline, the ICH Experts have developed a series of Q but it should primarily present the conclusions and implications of those data, and should not recapitulate them. Specifically, the Clinical Summary should
6、 provide a detailed factual summarisation of the clinical information in the CTD, and the Clinical Overview should provide a succinct discussion and interpretation of these findings together with any other relevant information (e.g., pertinent animal data or product quality issues that may have clin
7、ical implications). The Clinical Overview is primarily intended for use by regulatory agencies in the review of the clinical section of a marketing application. It should also be a useful reference to the overall clinical findings for regulatory agency staff involved in the review of other sections
8、of the marketing application. The Clinical Overview should present the strengths and limitations of the development program and study results, analyse the benefits and risks of the medicinal product in its intended use, and describe how the study results support critical parts of the prescribing inf
9、ormation. In order to achieve these objectives the Clinical Overview should: describe and explain the overall approach to the clinical development of a medicinal product, including critical study design decisions. assess the quality of the design and performance of the studies, and include a stateme
10、nt regarding GCP compliance. provide a brief overview of the clinical findings, including important limitations (e.g., lack of comparisons with an especially relevant active comparator, or absence of information on some patient populations, on pertinent endpoints, or on use in combination therapy).
11、provide an evaluation of benefits and risks based upon the conclusions of the relevant clinical studies, including interpretation of how the efficacy and safety findings support the proposed dose and target indication and an evaluation of how prescribing information and other approaches will optimis
12、e benefits and manage risks. address particular efficacy or safety issues encountered in development, and how they have been evaluated and resolved. explore unresolved issues, explain why they should not be considered as barriers to approval, and describe plans to resolve them. explain the basis for
13、 important or unusual aspects of the prescribing information. The Clinical Overview should generally be a relatively short document (about 30 pages). The length, however, will depend on the complexity of the application. The use of graphs and concise tables in the body of the text is encouraged for
14、brevity and to facilitate understanding. It is not intended that material presented fully elsewhere be repeated in the Clinical Overview; cross-referencing to more detailed presentations provided in the Clinical Summary or in Module 5 is encouraged. 1 The Common Technical Document Efficacy Table of
15、Contents 2.5.1 Product Development Rationale 2.5.2 Overview of Biopharmaceutics 2.5.3 Overview of Clinical Pharmacology 2.5.4 Overview of Efficacy 2.5.5 Overview of Safety 2.5.6 Benefits and Risks Conclusions 2.5.7 Literature References Detailed Discussion of Content of the Clinical Overview Section
16、s 2.5.1 Product Development Rationale The discussion of the rationale for the development of the medicinal product should: identify the pharmacological class of the medicinal product. describe the particular clinical/pathophysiological condition that the medicinal product is intended to treat, prevent, or diagnose (the targeted indication). briefly summarise the scientific background that supported the inve
